
|Articles|July 1, 2004
Combo yields results
Maxim Pharmaceuticals has announced that advanced metastatic melanoma patients treated with a combination of Ceplene and Interleukin-2 (IL-2) showed improved survival rates in a phase 3 trial, according to a Business Wire report.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
2
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
5











